ClinicalTrials.Veeva

Menu

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

N

Navy General Hospital, Beijing

Status and phase

Enrolling
Phase 2

Conditions

Diffuse Large B-cell Lymphoma

Treatments

Drug: Zanubrutinib plus Lenalidomide as Maintenance Therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT06503263
ZLDLBCL2024

Details and patient eligibility

About

The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.

Full description

The investigators will evaluate safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with diffuse large B-cell lymphoma post complete remission and have completed planed courses of chemotherapy . Event-free survival (EFS), progression-free survival (PFS), overall survival (OS), adverse events (AEs) will be assessed.

Enrollment

240 estimated patients

Sex

All

Ages

14+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;
  • Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
  • Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted;
  • Patient is willing and able to adhere to the study visit schedule and other protocol requirements;
  • Patient has recieved complete remission and has completed planed courses of chemotherapy
  • Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10^9/L (≥ 1 x 10^9/L if bone marrow (BM) involvement by lymphoma);Platelet ≥ 75 x 10^9/L (≥ 50 x 10^9/L if BM involvement by lymphoma); Hemoglobin ≥ 8 g/dL. Anticipated life expectancy at least 3 months

Exclusion criteria

  • Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;
  • Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;
  • Pregnant or lactating women

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

240 participants in 2 patient groups

Maintenance Therapy
Experimental group
Description:
Patients were treated by Zanubrutinib plus Lenalidomide as Maintenance Therapy
Treatment:
Drug: Zanubrutinib plus Lenalidomide as Maintenance Therapy
No maintenance Therapy
No Intervention group
Description:
Patients received no maintenance Therapy

Trial contacts and locations

1

Loading...

Central trial contact

Liren Qian, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems